BioMarin Announces Appointment of Ian T. Clark to Board of Directors
BioMarin Pharmaceutical (Nasdaq: BMRN) has appointed Ian T. Clark to its Board of Directors, effective August 1, 2025. Clark, the former CEO of Genentech (2010-2016), brings significant industry experience, having overseen the launch of 15 new drugs during his tenure. Prior to Genentech, he held senior positions at major pharmaceutical companies including Novartis, Sanofi, Ivax, and G.D. Searle.
Clark currently serves on the boards of several biotech companies including Olema Oncology, Takeda Pharmaceutical, and Guardant Health. He is also an advisor to KKR & Co. Inc. His appointment brings valuable expertise in drug development and commercialization to BioMarin's board.
BioMarin Pharmaceutical (Nasdaq: BMRN) ha nominato Ian T. Clark nel suo Consiglio di Amministrazione, con effetto dal 1掳 agosto 2025. Clark, ex CEO di Genentech (2010-2016), porta con s茅 una vasta esperienza nel settore, avendo supervisionato il lancio di 15 nuovi farmaci durante il suo mandato. Prima di Genentech, ha ricoperto ruoli di vertice in importanti aziende farmaceutiche come Novartis, Sanofi, Ivax e G.D. Searle.
Attualmente Clark fa parte dei consigli di amministrazione di diverse societ脿 biotecnologiche, tra cui Olema Oncology, Takeda Pharmaceutical e Guardant Health. Inoltre, 猫 consulente per KKR & Co. Inc. La sua nomina arricchisce il consiglio di BioMarin con competenze preziose nello sviluppo e nella commercializzazione di farmaci.
BioMarin Pharmaceutical (Nasdaq: BMRN) ha nombrado a Ian T. Clark en su Junta Directiva, con efecto a partir del 1 de agosto de 2025. Clark, ex CEO de Genentech (2010-2016), aporta una amplia experiencia en la industria, habiendo supervisado el lanzamiento de 15 nuevos medicamentos durante su gesti贸n. Antes de Genentech, ocup贸 cargos ejecutivos en importantes compa帽铆as farmac茅uticas como Novartis, Sanofi, Ivax y G.D. Searle.
Actualmente, Clark forma parte de los consejos de varias empresas biotecnol贸gicas, incluyendo Olema Oncology, Takeda Pharmaceutical y Guardant Health. Tambi茅n es asesor de KKR & Co. Inc. Su nombramiento aporta una valiosa experiencia en desarrollo y comercializaci贸n de medicamentos a la junta de BioMarin.
BioMarin Pharmaceutical (雮橃姢雼�: BMRN)鞚赌 Ian T. Clark毳� 2025雲� 8鞗� 1鞚茧秬韯� 鞚挫偓須� 氅る矂搿� 鞛勲獏頄堨姷雼堧嫟. Clark鞚赌 Genentech鞚� 鞝� CEO(2010-2016)搿� 鞛瀯 旮瓣皠 霃欖晥 15臧滌潣 鞁犾暯 於滌嫓毳� 齑濌磩頃橂姅 霌� 頀嶋秬頃� 鞐呹硠 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Genentech 鞚挫爠鞐愲姅 Novartis, Sanofi, Ivax, G.D. Searle 霌� 欤检殧 鞝滌暯靷棎靹� 瓿犾渼歆侅潉 鞐瀯頄堨姷雼堧嫟.
順勳灛 Clark鞚赌 Olema Oncology, Takeda Pharmaceutical, Guardant Health 霌� 鞐煬 氚旍澊鞓ろ厤 旮办梾鞚� 鞚挫偓須岇棎 彀胳棳頃橁碃 鞛堨溂氅�, KKR & Co. Inc.鞚� 鞛愲鞐弰 毵￡碃 鞛堨姷雼堧嫟. 攴胳潣 鞛勲獏鞚赌 BioMarin 鞚挫偓須岇棎 鞁犾暯 臧滊皽 氚� 靸侅梾頇� 攵勳暭鞚� 攴�欷戫暅 鞝勲靹膘潉 雿旐暣欷� 瓴冹瀰雼堧嫟.
BioMarin Pharmaceutical (Nasdaq : BMRN) a nomm茅 Ian T. Clark au sein de son Conseil d'administration, 脿 compter du 1er ao没t 2025. Clark, ancien PDG de Genentech (2010-2016), apporte une vaste exp茅rience dans le secteur, ayant supervis茅 le lancement de 15 nouveaux m茅dicaments durant son mandat. Avant Genentech, il a occup茅 des postes de direction dans de grandes entreprises pharmaceutiques telles que Novartis, Sanofi, Ivax et G.D. Searle.
Clark si猫ge actuellement aux conseils d'administration de plusieurs soci茅t茅s biotechnologiques, notamment Olema Oncology, Takeda Pharmaceutical et Guardant Health. Il est 茅galement conseiller aupr猫s de KKR & Co. Inc. Sa nomination apporte une expertise pr茅cieuse en d茅veloppement et commercialisation de m茅dicaments au Conseil de BioMarin.
BioMarin Pharmaceutical (Nasdaq: BMRN) hat Ian T. Clark mit Wirkung zum 1. August 2025 in den Vorstand berufen. Clark, der ehemalige CEO von Genentech (2010-2016), bringt umfassende Branchenerfahrung mit und hat w盲hrend seiner Amtszeit die Markteinf眉hrung von 15 neuen Medikamenten geleitet. Vor seiner Zeit bei Genentech bekleidete er leitende Positionen bei gro脽en Pharmaunternehmen wie Novartis, Sanofi, Ivax und G.D. Searle.
Derzeit sitzt Clark in den Aufsichtsr盲ten mehrerer Biotech-Unternehmen, darunter Olema Oncology, Takeda Pharmaceutical und Guardant Health. Zudem ist er Berater bei KKR & Co. Inc. Seine Ernennung bringt wertvolles Fachwissen in der Arzneimittelentwicklung und -vermarktung in den BioMarin-Vorstand.
- Appointment of highly experienced former Genentech CEO with track record of 15 drug launches
- Addition of board member with extensive industry connections and current board positions at major pharma companies
- Strengthened leadership oversight with executive experienced in drug development and commercialization
- None.
Mr. Clark served as Chief Executive Officer of Genentech and a member of the company's Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to serving as CEO, Mr. Clark held a number of senior management positions at Genentech. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals and G.D. Searle. Mr. Clark serves as a member of the boards of directors of Olema Oncology, Takeda Pharmaceutical Company Ltd., Kyverna Therapeutics, Inc., Corvus Pharmaceuticals, Inc. and Guardant Health, Inc. Mr. Clark previously served on the boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Avrobio, Inc. and Kite Pharma, Inc. Mr. Clark is currently an advisor to KKR & Co. Inc., and previously served on the board of the Biotechnology Industry Organization, as well as a member of the 12th District Economic Advisory Council of the Federal Reserve.
"We are very pleased to welcome Ian to our Board of Directors," said听Alexander Hardy, President and Chief Executive Officer of听BioMarin. "Ian is a well-respected leader, who has been involved in the development and launch of numerous new therapies for patients with unmet needs. His experience over three decades as a biopharmaceutical industry executive and board director will bring valuable perspective, making him an ideal addition to our Board."
"I am delighted to join BioMarin's Board, as the company continues to advance important new medicines for people with genetically defined conditions," said Mr. Clark. "I look forward to working with BioMarin to reach more patients around the world."
About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The听San Rafael,
Forward-Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: expectations regarding the addition of Mr. Ian Clark to BioMarin's Board of Directors and BioMarin's strategy execution and advancement of new medicines. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: finalizing the appointment of Mr. Clark, BioMarin's success in the commercialization of its commercial products, impacts of macroeconomic and other external factors on BioMarin's operations; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; BioMarin's ability to successfully manufacture its commercial products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin庐听is a registered trademark of BioMarin Pharmaceutical Inc.
Contacts: | |
Investors | Media |
罢谤补肠颈听惭肠颁补谤迟测听 | Erin听Rau |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558听 | (925) 683-9622 |
听
View original content to download multimedia:
SOURCE BioMarin Pharmaceutical Inc.
FAQ
Who is Ian T. Clark and why did BioMarin (BMRN) appoint him to their board?
What is Ian Clark's experience in the pharmaceutical industry?
What other board positions does Ian Clark currently hold?
How many new drugs were launched under Ian Clark's leadership at Genentech?
